Outcome of the Board Meeting held on November 14, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vanta Bioscience's board approved unaudited standalone and consolidated financial results for the half year ended September 30, 2025. Standalone revenue from operations fell sharply to Rs. 30.18 lakhs from Rs. 80.09 lakhs in the same period last year, a drop of about 62%. The company reported a standalone net loss of Rs. 181.32 lakhs (vs Rs. 129.34 lakhs loss a year ago), with consolidated net loss at Rs. 181.89 lakhs. Total expenses stood at Rs. 216.23 lakhs (standalone), exceeding revenues by a wide margin. EPS worsened to Rs. (2.55) standalone and Rs. (2.56) consolidated. The statutory auditor issued an unmodified limited review report with no qualifications. The subsidiary (Vanta Clinical Research Limited) remains largely inactive with near-zero revenues.
Continued revenue erosion combined with widening losses and negative operating cash flow (Rs. 321.78 lakhs standalone) signals serious business stress for shareholders. The company is funding losses through fresh borrowings rather than operations, which raises sustainability concerns despite the clean audit opinion.